Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
US12372533B2 · kind B2 · utility
0Cited by
6References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 3, 2020 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Feb 25, 2044 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.